Results 51 to 60 of about 99,547,245 (298)
Tumor infiltrating cells from paired melanoma tissue (N=5 pre-Ipi; N=5 post-Ipi) were analyzed by CyTOF. The impact of ipilimumab on the intratumoral frequency of A) CD3+CD4+FOXP3+CTLA-4+ (Tregs), B) CD3+CD4+FOXP3-CTLA-4+ T cells, and C) CD3+CD4+FOXP3 ...
Padmanee Sharma (8133285) +8 more
core +1 more source
Supplementary Data from Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited ...
Andrew Sharabi (3158010) +15 more
core +1 more source
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira +7 more
wiley +1 more source
CTLA-4: Not All Costimulation Is Stimulatory [PDF]
To activate a T cell, it was widely accepted, even in the 1960s, that there had to be a “signal one,” namely, receptor recognition of a foreign Ag. That fact did not make it less exciting when, in the early 1980s, Abs to the TCR were generated and the genes that encode it identified ([1][1 ...
Hugh, Auchincloss, Laurence A, Turka
openaire +2 more sources
PDF file - 206K, Supplemental Figure S1. Equivalent binding of anti-CTLA-4 isotypes to cell surface CTLA-4. Supplemental Figure S2. Serum concentrations of anti-CTLA-4 isotypes in C57BL/6 mice. Supplemental Figure S3.
Mark J. Selby (3110964) +6 more
core +1 more source
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a crucial immune checkpoint that is constitutively expressed in regulatory T (Treg) cells. Following T-cell activation, CTLA-4 is rapidly mobilized from its intracellular vesicle pool to the cell surface to ...
Laura Gámez-Díaz +2 more
doaj +1 more source
In vitro generation of regulatory T cells: A challenging tool for studying immune aging in humans
In vitro induction of human regulatory T cells using standard protocols generates suppressive, Foxp3‐expressing CD4+ T cells independently of TGF‐β supplementation and donor age. Regulatory T (Treg) cells play a key role in immune tolerance and homeostasis.
Lynn Muller +3 more
wiley +1 more source
Polymorphic sites at the immunoregulatory CTLA-4 gene are associated with chronic chagas disease and its clinical manifestations. [PDF]
BACKGROUND:Chagas disease affects approximately 10 million people mainly in Latin America. The immune regulation by the host seems to be an essential factor for disease evolution, and immune system inhibitory molecules such as CTLA-4 and PD-1 favor the ...
Fabrício C Dias +11 more
doaj +1 more source
CTLA-4: From conflict to clinic [PDF]
CTLA-4 was first identified in 1991 as a second receptor for the T cell costimulation ligand B7. Uncertainties about its biological function plagued the early years after its discovery until 1995, when it was confirmed to be an inhibitor of T cell responses.
openaire +2 more sources

